Traders assign an 82% implied probability to no Encore Medical IPO before June 2026 because the company’s planned May 2026 listing window on NYSE American has elapsed without pricing or trading, reflecting persistent delays in its $15 million S-1 offering. Encore Medical, a developer of transcatheter septal occlusion devices, filed its registration statement in September 2025 and set terms at $5 per share to fund ongoing FDA clinical trials for stroke and migraine indications. Recent market volatility in small-cap healthcare IPOs, coupled with the firm’s pre-revenue status and heavy reliance on clinical milestones, has likely prompted underwriters to postpone amid uncertain investor demand. This leaves the path to a 45–55 million closing market cap contingent on a swift re-filing or accelerated trial data release in the coming weeks.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日2026年6月以前にIPOしない 82%
4,500万〜5,000万ドル 6%
50M–55M 4.0%
5,500万ドル以上 4.0%
$24,088 Vol.
$24,088 Vol.
2026/04/22
4,500万ドル未満
2%
4,500万〜5,000万ドル
6%
50M–55M
4%
5,500万ドル以上
4%
2026年6月以前にIPOしない
82%
2026年6月以前にIPOしない 82%
4,500万〜5,000万ドル 6%
50M–55M 4.0%
5,500万ドル以上 4.0%
$24,088 Vol.
$24,088 Vol.
2026/04/22
4,500万ドル未満
$7,323 Vol.
2%
4,500万〜5,000万ドル
$2,625 Vol.
6%
50M–55M
$1,823 Vol.
4%
5,500万ドル以上
$3,121 Vol.
4%
2026年6月以前にIPOしない
$9,195 Vol.
82%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Traders assign an 82% implied probability to no Encore Medical IPO before June 2026 because the company’s planned May 2026 listing window on NYSE American has elapsed without pricing or trading, reflecting persistent delays in its $15 million S-1 offering. Encore Medical, a developer of transcatheter septal occlusion devices, filed its registration statement in September 2025 and set terms at $5 per share to fund ongoing FDA clinical trials for stroke and migraine indications. Recent market volatility in small-cap healthcare IPOs, coupled with the firm’s pre-revenue status and heavy reliance on clinical milestones, has likely prompted underwriters to postpone amid uncertain investor demand. This leaves the path to a 45–55 million closing market cap contingent on a swift re-filing or accelerated trial data release in the coming weeks.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
マーケット開始日： Apr 3, 2026, 7:59 PM ET
音量
$24,088終了日
2026/04/22マーケット開始日
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Traders assign an 82% implied probability to no Encore Medical IPO before June 2026 because the company’s planned May 2026 listing window on NYSE American has elapsed without pricing or trading, reflecting persistent delays in its $15 million S-1 offering. Encore Medical, a developer of transcatheter septal occlusion devices, filed its registration statement in September 2025 and set terms at $5 per share to fund ongoing FDA clinical trials for stroke and migraine indications. Recent market volatility in small-cap healthcare IPOs, coupled with the firm’s pre-revenue status and heavy reliance on clinical milestones, has likely prompted underwriters to postpone amid uncertain investor demand. This leaves the path to a 45–55 million closing market cap contingent on a swift re-filing or accelerated trial data release in the coming weeks.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
音量
$24,088終了日
2026/04/22マーケット開始日
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Traders assign an 82% implied probability to no Encore Medical IPO before June 2026 because the company’s planned May 2026 listing window on NYSE American has elapsed without pricing or trading, reflecting persistent delays in its $15 million S-1 offering. Encore Medical, a developer of transcatheter septal occlusion devices, filed its registration statement in September 2025 and set terms at $5 per share to fund ongoing FDA clinical trials for stroke and migraine indications. Recent market volatility in small-cap healthcare IPOs, coupled with the firm’s pre-revenue status and heavy reliance on clinical milestones, has likely prompted underwriters to postpone amid uncertain investor demand. This leaves the path to a 45–55 million closing market cap contingent on a swift re-filing or accelerated trial data release in the coming weeks.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問